Friday, October 22nd, 2021

Ketotifen tablets back in stock- October 22, 2021

Ketotifen (Zaditen) 1mg tablets are back in stock with Alloga, the UK distributors.  While it can take time for the product to travel to the pharmacies via wholesalers, pharmacies can order directly from Alloga and be invoiced by their usual wholesalers, which may speed up the process.


Wednesday, October 13th, 2021

Findings from UKMasto Survey on COVID-19 Vaccinations in Mastocytosis Published in the Journal HemaSphere

Using a survey, we sought to capture the experience of people with mast cell diseases when having their COVID-19 vaccination, beginning in February 2021.  We understood that these patients and their doctors could be concerned about how well the vaccinations would be tolerated.  We are pleased to share a peer-reviewed letter published today in HemaSphere, 


Friday, October 1st, 2021

Masto Family in West Sussex Featured in the News

Olivia is six and has recently been diagnosed with systemic mastocytosis after being diagnosed with cutaneous mastocytosis at the age of six months.  This weekend her aunts and her grandmother are running the Virtual London Marathon to raise money for The UK Mastocytosis Support Group.  Olivia’s mum, Charlotte Lane is a trustee of the charity 


Friday, September 10th, 2021

New supply of sodium cromoglycate capsules in stock

We are very pleased to share that there are now two new licensed sodium cromoglycate products that we hope will meet all or at least much of the demand over the next several months. The Department of Health and Social Care have informed us that during the week ending 17 September, Somex Pharmaceuticals will begin 


Thursday, August 19th, 2021

Midostaurin to Be Funded by NHS After Campaign by UKMasto and Leukaemia Care

The UK Mastocytosis Support Group and Leukaemia Care successfully campaign for patients with Advanced Systemic Mastocytosis (AdvSM) to access new treatment The National Institute for Health and Care Excellence (NICE) have today made recommendations for midostaurin to become an NHS treatment option for advanced systemic mastocytosis (AdvSM) patients in England. Advanced SM is used to